Beyond the Pill: When Software Becomes Part of the Label

The conversation around PDURS is entering a more practical phase. Since our previous HLTH roundtable on Digital Pills + Platforms, interest in software-enabled therapies has continued to grow across pharma, digital health, and commercial strategy teams. At the same time, organizations are facing the realities of what it actually takes to operationalize these models inside large, regulated healthcare environments.

While enthusiasm remains high, adoption has been slower and more fragmented than many initially expected. Questions around ownership, evidence requirements, commercialization strategy, reimbursement, and long-term value creation are still being worked through across the industry. Many organizations are exploring software-enabled therapies in targeted areas such as adherence, patient engagement, monitoring, and therapy differentiation, but few have yet established scalable operating models.

This follow-on roundtable builds directly on the themes raised during our previous PDURS discussion and shifts the focus toward implementation, execution, and commercial maturity. Participants will explore where organizations are seeing meaningful traction, what barriers continue to slow adoption, and how software-enabled therapies may evolve from isolated pilots into integrated components of pharmaceutical strategy and patient care.

Join us to discuss:

• Where are organizations seeing the clearest opportunities for software-enabled therapies today?

• What operational, regulatory, and commercial challenges are slowing broader PDURS adoption?

• What will separate scalable software-enhanced therapeutic models from short-term experimentation over the next few years?